On or around 06/18/2013 (Date of order of final judgment)
Filing Date: June 15, 2012
According to the law firm press release, the complaint alleges that defendants mislead investors about the timing and success of AEterna’s clinical trial that tested whether the drug perifosine was effective in treating late stage colorectal cancer.
On April 2, 2012, AEterna shocked the market by disclosing that perifosine was ineffective in treating colorectal cancer. This news caused AEterna stock to drop approximately 66% by the close of the business day.
On September 4, 2012, the Court issued an Order appointing lead plaintiff and approving the selection of lead counsel.
On November 5, 2012, the Plaintiffs filed an Amended Complaint. On December 21, Plaintiffs followed with a Second Amended Complaint.
On May 29, 2013, the Court issued an Order granting the Defendants' motion to dismiss and denying the Plaintiff's motion to strike. The dismissal was with prejudice.
Company & Securities Information
Defendant: AEterna Zentaris Inc.
Industry: Biotechnology & Drugs
Ticker Symbol: AEZS
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Charles Austin, et al. v. AEterna Zentaris Inc., et al.